Physician profile
Robin Abdelmalik
NPI 1275656662
$11,510.78
in general payments reported to CMS, 2019-2025
47 companies · $2,496 in 2025
The $2,496 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,097 · 2020: $990 · 2021: $1,750 · 2022: $1,690 · 2023: $1,896 · 2024: $1,593 · 2025: $2,496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,985.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,984.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,378.28 | 2020-2025 | Jot Dx, Cardiomems, Aveir |
| Medtronic, INC. | $1,326.91 | 2021-2025 | Symplicity G3, Linq II, Onyx Frontier |
| Novartis Pharmaceuticals Corporation | $942.80 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $796.84 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $670.54 | 2019-2025 | Farxiga, Wainua, Andexxa |
| Janssen Pharmaceuticals, INC | $470.55 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $444.00 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $420.97 | 2021-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $405.41 | 2019-2025 | Jardiance |
| Pfizer INC. | $401.82 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $306.83 | 2022-2024 | Optimizer, Optimizer |
| Cvrx, INC. | $305.48 | 2020-2025 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $303.58 | 2019-2024 | |
| Amgen INC. | $295.15 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $289.02 | 2020-2025 | Nexletol |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $268.03 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Scpharmaceuticals INC. | $254.16 | 2024-2025 | |
| Boston Scientific Corporation | $232.12 | 2022-2025 | Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd, Watchman Flx |
| Medtronic Vascular, INC. | $221.39 | 2019-2020 | |
| Amarin Pharma, INC. | $184.18 | 2019-2022 | |
| Inspire Medical Systems, INC. | $151.84 | 2023-2025 | Inspire |
| Heartflow, INC. | $151.42 | 2024-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $139.13 | 2021-2023 | Arcalyst |
| Altathera Pharmaceuticals LLC | $130.52 | 2025 | Sotalol Hydrochloride |
| Philips North America LLC | $103.14 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, (5091) Amb Mon & Diag Und |
| Abiomed | $95.58 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $95.31 | 2024 | Arcalyst |
| Biotronik INC. | $60.22 | 2019-2024 | Biomonitor |
| Gilead Sciences, INC. | $57.74 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $56.19 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $55.70 | 2019-2025 | Evkeeza |
| Daiichi Sankyo INC. | $54.56 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $52.58 | 2021-2025 | Uptravi, Opsumit |
| Irhythm Technologies, INC. | $43.37 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Akcea Therapeutics, INC. | $41.19 | 2021 | |
| Arbor Pharmaceuticals, INC. | $36.03 | 2019 | |
| Inari Medical, INC. | $35.18 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Stryker Corporation | $34.17 | 2025 | Flowtriever |
| Bardy Diagnostics, INC. | $34.00 | 2020-2021 | |
| Astellas Pharma US INC | $32.27 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $29.49 | 2019-2021 | |
| Edwards Lifesciences Corporation | $25.45 | 2020 | |
| Cardiovascular Systems INC. | $20.08 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.83 | 2025 | |
| Davol INC. | $17.30 | 2020 | |
| Baxter Healthcare | $14.54 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Itamar Medical INC | $7.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Abdelmalik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.